Kirby Gabrys, MD
Nephrology · Albuquerque, NMNPI 1134141260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.
Across 95 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$415
- Bayer$379
- AstraZeneca$195
- Akebia Therapeutics Inc$172
- Medtronic$163
- Nxstage Medical, Inc.$148
- plus $922 from 21 others
What the payments were for
- Food & beverage$2,16090%
- Education$23410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 12 | $415 |
| Bayer | 16 | $379 |
| AstraZeneca(2 entities) | 10 | $195 |
| Akebia Therapeutics Inc | 3 | $172 |
| Medtronic | 1 | $163 |
| Nxstage Medical, Inc. | 5 | $148 |
| Vifor Pharma, Inc. | 8 | $123 |
| Aurinia Pharma U.S., Inc. | 4 | $92 |
| GSK | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Fresenius USA Marketing, Inc. | 3 | $54 |
| Mallinckrodt Hospital Products Inc. | 3 | $54 |
| Travere Therapeutics, Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $51 |
| Novo Nordisk | 2 | $46 |
| Lilly USA, LLC | 2 | $45 |
| Veloxis Pharmaceuticals, Inc. | 1 | $37 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Calliditas Therapeutics US Inc. | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Abiomed | 1 | $24 |
| Vantive US Healthcare LLC | 1 | $22 |
| Ardelyx, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $18 |
| Covidien LP | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONYX FRONTIER$163
- Kerendia$125
- Vafseo$118
How this compares
$2,394 in reported general payments places this provider in the 65th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 21 | $70,763 |
| KerendiaFinerenone | 46 | $44,995 |
| FarxigaDapagliflozin Propanediol | 40 | $32,169 |
| EliquisApixaban | 15 | $16,004 |
| EntrestoSacubitril/Valsartan | 12 | $11,935 |
| OzempicSemaglutide | 12 | $10,665 |
| Lanthanum Carbonate | 14 | $9,876 |
| Sevelamer Carbonate | 34 | $9,456 |
| Bumetanide | 47 | $2,504 |
| Tacrolimus | 33 | $2,259 |
| Furosemide | 126 | $1,801 |
| Amlodipine Besylate | 164 | $1,750 |
| Pregabalin | 27 | $1,743 |
| Cinacalcet Hcl | 13 | $1,408 |
| Hydralazine Hcl | 75 | $1,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $54 | $70,76321 claims |
| BayerKerendia | $379 | $44,99546 claims |
| AstraZenecaFarxiga | $195 | $32,16940 claims |
| Novo NordiskOzempic | $46 | $10,66512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Albuquerque
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
- Chudi AdiAlbuquerque$7K
- Dale EricksonAlbuquerque$6K
- Lei ChenAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.